GEN Exclusives

More »

GEN News Highlights

More »
Jan 14, 2013

Kyowa Hakko Kirin Expands Collaborator Stable

  • Kyowa Hakko Kirin has formed another alliance to advance its drug discovery programs, this time focused on fragment-based discovery and featuring NovAliX.

    The companies will collaborate to develop drug candidates against protein-protein interaction targets. NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise.

    For its efforts NovAliX will receive technology access fees as well as further research funding payments and milestones.

    Kyowa Hakko Kirin has inked a number of alliances in the last six months. In November it partnered with Activiomics, which is applying its TIQUAS phosphoproteomics platform to elucidate signaling mechanisms of lead compounds in relevant cell-based systems.

    In June, Kyowa partnered with Otsuka to advance its diabetes and oncology programs.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

GEN Poll

More » Poll Results »

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?